secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0000950170-25-088494
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455
----------------------------------------------------------------------------

- Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.
- Net proceeds ~$7.45M; funds for clinical development, working capital, and general corporate purposes.
- Mipletamig (CD123xCD3) shows 85% remission rate in evaluable frontline AML patients in RAINIER trial; no CRS in first two cohorts.
- Cohort 3 nears full enrollment at highest dose; mipletamig triplet therapy enables transplant in previously ineligible patient.
- New preclinical candidate APVO455 (Nectin-4xCD3) added to CD3-targeted pipeline using CRIS-7 domain; targets solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/0000950170-25-088494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025088494/apvo-20250618.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-088494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer